Skip to main content

National Population Insights (4.28.2023)

Apr 28, 2023 5:00 am

Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.

  1. A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37)
  2. Brazil study of 1,528 kid lupus (cSLE) shows low mortality (4.1%, n=63); 84%F, age 12 yrs w/ time to death=3.2yrs post-Dx. Cause?1) Sepsis (43%), 2) opportunistic infx(11%), & 3) Pulm hemorrhage (9.5%). Predictors: CNS lupus (HR 2.6) & CKD (HR 4.3)
  3. Finnish population study involving 4180 #JIA patients followed for 6+ years (betw mean ages of 8.3 to 14.8 years), finds that 13% of the JIA patients prescribed psychotropic drugs (vs 10% in controls; p<0.001). Antidepressant use most freq, esp in females
  4. NIH generated FDA approved drug costs ~$1.4-1.7 billlion for each 1st-in-class drug (vs estimated pharma industry cost of $1.5 billion per approved Rx). Govt may serve as early investor in pharma innovations. ~1/2 total R&D investment comes from US govt
  5. Denosumab Reduces Type II Diabetes Risk     
  6. A Rising Gout Risk in Asians 
    • Dr. Sepulvado - Seropositive Rheumatoid arthritis with Septic arthritis on MTX and infliximab biosimilar – Whats next?  RABBIT Risk Calculator   
    • Dr. Wasser – Alopecia Universalis with hearing loss – what’s the association and Rx?
    • Dr Shams 1) hx of H. zoster, use JAKi?  2) JAKi lipids elevations – how to manage


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has received compensation as an advisor or consultant on this subject